The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

US pharma major Bristol Myers Squibb (NYSE: BMY) saw its shares fall 4% in after-hours trading on Tuesday, after it announced ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

BMS said it will launch Cobenfy within the next few weeks and has set a price of $1,850 per month for the medicine, which is considerably more than the current, largely generic array of ...

Cobenfy, Bristol Myers Squibb’s once-promising schizophrenia drug, just failed its Phase III ARISE trial as an add-on therapy ...

Cobenfy can be produced in the US initially but if International markets introduce reciprocal tariffs BMS may have to use its international manufacturing facilities to produce the drug for these ...

Positive top-line results from the Phase III EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of Cobenfy (xanomeline and trospium chloride) in ...

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy ...